News
CERT
5.40
+1.12%
0.06
Weekly Report: what happened at CERT last week (0615-0619)?
Weekly Report · 1d ago
Analyst Maintains Hold on Certara Amid Leadership Transition and Execution Risks
TipRanks · 5d ago
Certara Names Faiz Mohammed As Interim CFO As Gallagher Resigns
NASDAQ · 6d ago
Certara Appoints Interim CFO Amid Leadership Transition
TipRanks · 6d ago
Certara names Faiz Mohammed interim CFO as John Gallagher steps down
Seeking Alpha · 6d ago
Certara CFO John Gallagher Resigns
Dow Jones · 6d ago
Certara announces CFO transition; affirms FY26 guidance
TipRanks · 6d ago
*Certara Reaffirms 2026 Guidance >CERT
Dow Jones · 6d ago
*Certara: Faiz Mohammed, Senior VP of Finance and Treasurer, to Serve as Interim CFO
Dow Jones · 6d ago
*Certara : John Gallagher, CFO, to Resign, Effective End of Day on July 14 >CERT
Dow Jones · 6d ago
*Certara Has Launched Search With Leading Executive Search Firm for New CFO >CERT
Dow Jones · 6d ago
Certara CFO John Gallagher to step down July 14, Faiz Mohammed named interim CFO
PUBT · 6d ago
CERTARA - FAIZ MOHAMMED TO SERVE AS INTERIM CFO UPON GALLAGHER'S DEPARTURE
Reuters · 6d ago
Press Release: Certara Announces CFO Transition
Dow Jones · 6d ago
Certara Announces CFO Transition
Barchart · 6d ago
Analysts’ Top Healthcare Picks: Certara (CERT), CareDx (CDNA)
TipRanks · 6d ago
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?
Simply Wall St · 6d ago
Top Biotech Gainers: CRVO On Watch, SLP Scooped Up, LNAI Back In Compliance, NTHI Advances NEO212
NASDAQ · 06/17 03:02
Certara Rated Buy as Peer Deal Underscores Discounted Valuation and Supports Long-Term Growth Upside
TipRanks · 06/16 14:35
Leerink says Certara peer acquisition supports higher multiple
TipRanks · 06/16 14:30
More
Webull provides a variety of real-time CERT stock news. You can receive the latest news about Certara, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CERT
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions, providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,600 biopharmaceutical companies, academic institutions and biotech companies across 70 countries.